Roflumilast as add-on Therapy in Early Cases of ARDS

Summary

* Mild cases of ARDS will be included in a two-arm protocol, to receive 500 mcg of roflumilast daily up to 28 days (FDA approved dose for COPD) plus standard of care versus standard of care alone. * Approximately 76 hospitalized patients with ARDS will be enrolled in this study. * Eligible patients will be randomized at ratio of (1:1) to receive either roflumilast plus standard of care or standard of care alone.

Timeline

Start

2021-03-21

Primary completion

2021-12-30

Completion

2022-01-01

Drugs

Indications